Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I3 | Q14994 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.37 |
| ▸ | SCD | O00767 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.35 |
| ▸ | LIPC | P11150 | 1/20 | 0.35 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.35 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1360955 | 0.92 | NR1I3 (0.35) | NR1I3SMN1; SMN2HSP90AA1LMNASCD | |
| SCHEMBL12138920 | 0.92 | SCD (0.39) | NR1I3SMN1; SMN2LMNASCDMAPT | |
| SCHEMBL1360972 | 0.89 | MAPT (0.42) | NR1I3MAPT | |
| SCHEMBL1360637 | 0.85 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNAMAPTHSD17B13 | |
| SCHEMBL823398 | 0.85 | SMN1; SMN2 (0.41) | NR1I3SMN1; SMN2HSP90AA1LMNARNASEH1 | |
| SCHEMBL12140554 | 0.85 | NR1I3 (0.40) | NR1I3SMN1; SMN2HSP90AA1LMNASCD | |
| SCHEMBL1361685 | 0.83 | NR1I3 (0.39) | NR1I3SMN1; SMN2HSP90AA1LMNASCD | |
| SCHEMBL1151264 | 0.82 | SMN1; SMN2 (0.39) | SMN1; SMN2HSP90AA1LMNARNASEH1SCD | |
| SCHEMBL12140420 | 0.77 | MAPT (0.35) | NR1I3SMN1; SMN2HSP90AA1LMNASCD | |
| SCHEMBL1359102 | 0.77 | AXL (0.39) | SMN1; SMN2LMNASCDHSD17B13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426405-B2 | Thiazopyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2013-04-23 | — | — | US | disclosed |
| US-8426405-B2 | Thiazopyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2013-04-23 | — | — | US | disclosed |
| US-8426405-B2 | Thiazopyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2013-04-23 | — | — | US | disclosed |
| EP-2247601-B1 | THIAZOPYRIMIDINONES AND USES THEREOF | AVEXA LTD (AU) | 2013-04-10 | — | — | EP | disclosed |
| US-20110281861-A1 | THIAZOPYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-11-17 | — | — | US | disclosed |
| US-20110281861-A1 | THIAZOPYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-11-17 | — | — | US | disclosed |
| US-20110281861-A1 | THIAZOPYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-11-17 | — | — | US | disclosed |
| WO-2010000030-A1 | THIAZOPYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281861-A1 | THIAZOPYRIMIDINONES AND USES THEREOF | TPMT, CYP2C19, CYP3A5 | NR1I3 1003/4885SMN1; SMN2 1592/4885HSP90AA1 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.